DrRoberto Firpi-Morell

A Phase 2b Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of CNP-104 in Adults with Primary Biliary Cholangitis

Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

Kowa K-808-2.01 A Phase 2, Randomized, Placebo-controlled,Parallel Group, Multi center 12-week Study with a 52-week Extensionto Evaluate Effi cacy and Safety of Two Doses of K-808 (Pemafi brate)in Subjects with Primary Biliary Cholangiti s with Inadequate Responseto Ursodeoxycholic Acid and/or Obeti cholic Acid Treatment

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Nonalcoholic Fatty Liver Disease (NAFLD)

Akero AK-US-001-0105 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

The potential of kava in enabling tobacco cessation - its holistic effects in managing stress and insomnia associated with abstinence

A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Reducing tobacco-associated lung cancer risk: A randomized clinical trial of AB-free kava

A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

AASLD 2019 NP/PA CLINICAL HEP0ATOLOGY FELLOWSHIP PROGRAM

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) In Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.

A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection

Merck MK5172-017 "A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/orViral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have BeenPreviously Treated with MK-5172 in a Prior Clinical Trial"

Conatus IDN-6556-07 A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had HCV Reinfection & Liver Fibrosis following Orthotopic Liver Transplantation for HCV Infection & Who Subsequently Achieved a SVR Following anti-HCV Therapy

A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"

"AbbVie M14-490" An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic HCV Infection and Cirrhosis (TURQUOISE-III)